NASDAQ:ACOR

Acorda Therapeutics - ACOR Stock Forecast, Price & News

$0.30

+0.02 (+7.17%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.28
▼
$0.33
50-Day Range: $0.28
▼
$0.53
52-Week Range: $0.26
▼
$4.90

Volume: 190,329 shs
Average Volume: 202,267 shs
Market Capitalization: $7.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Acorda Therapeutics (NASDAQ:ACOR) Stock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Stock News Headlines

September 28, 2022 | americanbankingnews.com

Acorda Therapeutics (NASDAQ:ACOR) Now Covered by Analysts at StockNews.com

September 23, 2022 | finanznachrichten.de

Defence Therapeutics Inc.: Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative

September 8, 2022 | finance.yahoo.com

Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 29, 2022 | nasdaq.com

Acorda Enters License Agreement For Nepicastat

August 29, 2022 | finance.yahoo.com

Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

August 19, 2022 | nasdaq.com

Acorda Therapeutics COO Lauren Sabella To Resign

August 19, 2022 | finance.yahoo.com

Acorda Therapeutics Announces Resignation of Chief Operating Officer

August 7, 2022 | seekingalpha.com

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2022 Results - Earnings Call Transcript

August 7, 2022 | investing.com

Acorda Therapeutics Misses Q2 EPS by $2.79

August 7, 2022 | seekingalpha.com

Acorda Therapeutics Non-GAAP EPS of -$3.15, revenue of $31.05M

August 4, 2022 | finance.yahoo.com

Acorda Therapeutics Reports Second Quarter 2022 Financial Results

July 30, 2022 | morningstar.com

Acorda Therapeutics Inc Stock Quote ACOR

July 28, 2022 | finance.yahoo.com

Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022

June 16, 2022 | seekingalpha.com

Nano-cap biotech Acorda surges 50% on drug launch in Germany

June 16, 2022 | finance.yahoo.com

Why Acorda Therapeutics Shares Gaining Today?

June 16, 2022 | finance.yahoo.com

Esteve Launches INBRIJA® in Germany

June 14, 2022 | markets.businessinsider.com

Acorda Therapeutics, Inc. Provides Notice of Data Privacy Event

May 18, 2022 | nasdaq.com

Acorda Therapeutics Now the Least Expensive vs. Cardano This Year

May 14, 2022 | seekingalpha.com

Acorda Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

May 11, 2022 | seekingalpha.com

Acorda partners with Biopas to sell Parkinson's disease therapy in Latin America

May 11, 2022 | finance.yahoo.com

Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

May 11, 2022 | finance.yahoo.com

Acorda Therapeutics Reports First Quarter 2022 Financial Results

May 4, 2022 | finance.yahoo.com

Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

May 3, 2022 | finance.yahoo.com

Acorda Therapeutics, Inc. (ACOR)

March 30, 2022 | finance.yahoo.com

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Company Calendar

Last Earnings: 8/04/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ACOR
CUSIP: 00484M10
CIK: 1008848
Web: www.acorda.com
Phone: (914) 347-4300
Fax: 914-347-4560
Employees: 118
Year Founded: 1995

Profitability

EPS (Most Recent Fiscal Year): ($8.87)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-103,950,000.00
Net Margins: -98.25%
Pretax Margin: -86.60%
Return on Equity: -90.29%
Return on Assets: -27.37%

Debt

Debt-to-Equity Ratio: 2.10
Current Ratio: 1.86
Quick Ratio: 1.49

Sales & Book Value

Annual Sales: $129.07 million
Price / Sales: 0.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.49 per share
Price / Book: 0.02

Miscellaneous

Outstanding Shares: 24,280,000
Free Float: 23,768,000
Market Cap: $7.26 million
Optionable: Optionable
Beta: 0.45

Social Links

Key Executives

Dr. Ron Cohen M.D. (Age 66)
Founder, CEO, Pres & Director
Comp: $1.21M

Ms. Lauren M. Sabella (Age 61)
Chief Operating Officer
Comp: $740.7k

Dr. Burkhard Blank M.D. (Age 67)
Interim Head of Drug Safety
Comp: $1.36M

Mr. Michael A. Gesser M.B.A. (Age 59)
Chief Financial Officer

Mr. Robert Morales (Age 54)
Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller

Ms. Felicia Vonella
VP of Investor Relations

Mr. Neil S. Belloff Esq. (Age 62)
Gen. Counsel

Ms. Tierney Saccavino
Exec. VP of Corp. Communications

Ms. Denise J. Duca
Exec. VP of HR

Mr. Kerry M. Clem (Age 52)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACOR Stock - Frequently Asked Questions

How have ACOR shares performed in 2022?: Acorda Therapeutics' stock was trading at $2.39 at the beginning of 2022. Since then, ACOR shares have decreased by 87.5% and is now trading at $0.2990.
View the best growth stocks for 2022 here.
When is Acorda Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ACOR earnings forecast.
How were Acorda Therapeutics' earnings last quarter?: Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($2.78) EPS for the quarter, missing the consensus estimate of ($0.36) by $2.42. The biopharmaceutical company earned $31.05 million during the quarter. Acorda Therapeutics had a negative trailing twelve-month return on equity of 90.29% and a negative net margin of 98.25%.
When did Acorda Therapeutics' stock split?: Shares of Acorda Therapeutics reverse split on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 31st 2020. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?: 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).
What is Acorda Therapeutics' stock symbol?: Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How do I buy shares of Acorda Therapeutics?: Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acorda Therapeutics' stock price today?: One share of ACOR stock can currently be purchased for approximately $0.30.
How much money does Acorda Therapeutics make?: Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $7.26 million and generates $129.07 million in revenue each year. The biopharmaceutical company earns $-103,950,000.00 in net income (profit) each year or ($8.87) on an earnings per share basis.
How many employees does Acorda Therapeutics have?: The company employs 118 workers across the globe.
How can I contact Acorda Therapeutics?: Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560.

This page (NASDAQ:ACOR) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial